Wealth Enhancement Advisory Services LLC Acquires 3,269 Shares of Axon Enterprise, Inc. (NASDAQ:AXON)

Wealth Enhancement Advisory Services LLC raised its holdings in shares of Axon Enterprise, Inc. (NASDAQ:AXON) by 35.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 12,422 shares of the biotechnology company’s stock after acquiring an additional 3,269 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Axon Enterprise were worth $4,964,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also modified their holdings of the business. PFG Investments LLC raised its holdings in Axon Enterprise by 0.6% in the 3rd quarter. PFG Investments LLC now owns 3,872 shares of the biotechnology company’s stock worth $1,547,000 after purchasing an additional 25 shares during the period. Forsta AP Fonden raised its stake in shares of Axon Enterprise by 10.9% in the third quarter. Forsta AP Fonden now owns 15,300 shares of the biotechnology company’s stock worth $6,114,000 after buying an additional 1,500 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Axon Enterprise by 23.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,329 shares of the biotechnology company’s stock valued at $2,502,000 after buying an additional 1,196 shares in the last quarter. Allworth Financial LP grew its stake in shares of Axon Enterprise by 7.1% during the 3rd quarter. Allworth Financial LP now owns 1,006 shares of the biotechnology company’s stock valued at $402,000 after acquiring an additional 67 shares during the period. Finally, Cromwell Holdings LLC increased its holdings in Axon Enterprise by 94.0% in the 3rd quarter. Cromwell Holdings LLC now owns 227 shares of the biotechnology company’s stock worth $91,000 after acquiring an additional 110 shares in the last quarter. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Insider Transactions at Axon Enterprise

In related news, Director Michael Garnreiter sold 1,000 shares of Axon Enterprise stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $437.98, for a total value of $437,980.00. Following the completion of the transaction, the director now owns 26,259 shares in the company, valued at approximately $11,500,916.82. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, CEO Patrick W. Smith sold 80,300 shares of the firm’s stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $371.78, for a total value of $29,853,934.00. Following the completion of the sale, the chief executive officer now owns 3,015,366 shares in the company, valued at approximately $1,121,052,771.48. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Michael Garnreiter sold 1,000 shares of the company’s stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $437.98, for a total transaction of $437,980.00. Following the transaction, the director now owns 26,259 shares in the company, valued at $11,500,916.82. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 371,172 shares of company stock worth $137,000,162 in the last three months. Insiders own 6.10% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on AXON shares. The Goldman Sachs Group lifted their price target on shares of Axon Enterprise from $385.00 to $441.00 and gave the company a “buy” rating in a report on Wednesday, October 23rd. JMP Securities lifted their target price on shares of Axon Enterprise from $430.00 to $500.00 and gave the company a “market outperform” rating in a research note on Thursday. Needham & Company LLC upped their target price on shares of Axon Enterprise from $400.00 to $525.00 and gave the stock a “buy” rating in a report on Tuesday, October 22nd. Northland Securities raised their price target on Axon Enterprise from $330.00 to $365.00 and gave the company an “outperform” rating in a report on Thursday, August 8th. Finally, Barclays upped their price objective on Axon Enterprise from $381.00 to $387.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 7th. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat.com, Axon Enterprise presently has an average rating of “Moderate Buy” and an average price target of $388.23.

Axon Enterprise Stock Performance

NASDAQ:AXON opened at $423.50 on Friday. The company has a market cap of $31.96 billion, a price-to-earnings ratio of 123.83, a PEG ratio of 11.91 and a beta of 0.94. Axon Enterprise, Inc. has a 1 year low of $199.50 and a 1 year high of $455.17. The stock’s 50 day simple moving average is $400.22 and its two-hundred day simple moving average is $339.14. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.88 and a quick ratio of 2.52.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.18. Axon Enterprise had a net margin of 16.06% and a return on equity of 9.34%. The company had revenue of $504.00 million for the quarter, compared to analysts’ expectations of $478.35 million. During the same quarter in the previous year, the business posted $0.80 earnings per share. Axon Enterprise’s quarterly revenue was up 34.5% on a year-over-year basis. As a group, equities analysts anticipate that Axon Enterprise, Inc. will post 1.79 earnings per share for the current fiscal year.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.